Cravath, Weil Advise J&J In €1.75B Offer For Crucell
Johnson & Johnson, which owns 17.9 percent of the outstanding shares of Crucell NV, has announced plans to buy the remainder of the Dutch biotechnology firm for €1.75 billion ($2.4 billion)....To view the full article, register now.
Already a subscriber? Click here to view full article